Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck

Oncology

Volumn 63, Issue 2, 2002, Pages 145-150

  Gedlicka, C ^a   Formanek, M ^a   Selzer, E ^a   Burian, M ^a   Kornfehl, J ^a   Fiebiger, W ^a   Cartellieri, M ^a   Marks, B ^a   Kornek, Gabriela V ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cisplatin; Docetaxel; Head and neck cancer; Palliative chemotherapy

Indexed keywords

CISPLATIN; CORTICOSTEROID; DOCETAXEL; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; HYDRATION; MAJOR CLINICAL STUDY; METASTASIS; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SEPTICEMIA; SQUAMOUS CELL CARCINOMA; STEROID THERAPY; STOMATITIS; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HEAD AND NECK NEOPLASMS; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PALLIATIVE CARE; RECURRENCE; SURVIVAL RATE; TAXOIDS; TIME FACTORS;

EID: 0036380344     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000063809     Document Type: Article

References (20)

1. Schantz SP, Harrison LB, Forastiere A: Cancer of the head and neck; in De Vita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, Lippincott, 2001, ch 30, pp 789-917.
2. Everett E, Vokes EE, Ralph R, Weichselbaum RR, Scott M, Lippman SM, Hong WK: Head and neck cancer (review). N Engl J Med 1993;328:184-194.
3. Forastiere A: Head and neck cancer: Overview of recent developments and future directions. Semin Oncol 2000;27:1-4.
4. Khuri FR, Shin DM, Glisson BS, Lippman SM, Hong WK: Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Current status and future directions. Sem Oncol 2000;27:25-33.
5. Vokes EE, Athanasiadis I: Chemotherapy for squamous cell carcinoma: The future is now. Ann Oncol 1996;7:15-29.
6. Aapro M, Rowinsky E: Docetaxel: Assessing a range of activity. Anti-Cancer Drugs 2001;12(suppl):S1-S3.
7. Rowinsky EK: The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Ann Rev Med 1997;48:353-374.
8. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, Poulin MD, Thornhill L, Costello R, Posner MR: Docetaxel: An active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996;15:1672-1678.
9. Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, Franklin H, Le Bail N, Clavel M, Kaye SB: Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994;5:533-537.
10. Posner MR: Docetaxel in squamous cell cancer of the head and neck. Anti-Cancer Drugs 2001;12(suppl):S21-S24.
11. Colevas AD, Poster MR: Docetaxel in head and neck cancer. Am J Clin Oncol 1998;21:482-486.
12. Green MR: The current status of docetaxel for advanced non-small cell lung cancer. Anti-Cancer Drugs 2001;12(suppl):S11-S16.
13. Specht L, Kornum Larsen S, Sand Hansen H: Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous cell carcinoma of the head and neck. Ann Oncol 2000;11:845-849.
14. Schöffski P, Catimel G, Planting AST, Droz JP, Verweij J, Schrijvers D, Gras L, Schrijvers A, Wanders J, Hanauske AR: Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 1999;10:119-122.
15. Miller AB, Hoogstraten B, Staquet M: Reporting results of cancer treatment. Cancer 1981;147:207-214.
16. Gehan EA: The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J Chron Dis 1961;13:346-353.
17. Anderson JR, Bernstein L, Pike MC: Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis. Biometrics 1982;38:407-416.
18. Pignon JP, Bourhis J, Domenge C, Designé L: Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: Three meta-analyses of updated individual data. Lancet 2000;355:949-955.
19. Forastiere A, Metch B, Schuller D: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A southwest oncology group study. J Clin Oncol 1992;10:1245-1251.
20. Colevas AD, Adak S, Amrein PC, Barton JJ, Costello R, Poster MR: A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous cell carcinoma of the head and neck. Ann Oncol 2000;11:535-539.